MYL Mylan N.V.

+0.06  (0%)
Previous Close 31.24
Open 31.27
Price To book 1.31
Market Cap 16785587099
Shares 536,280,738
Volume 5,187,733
Short Ratio 2.39
Av. Daily Volume 7,041,653

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 9, 2017.
Neulasta biosimilar
PDUFA date originally set for September 3 extended by three months to December 3, 2017. Advisory Committee Meeting July 13, 2017 voted 16-0 recommending approval.
MYL-1401O - trastuzumab biosimilar
Trastuzumab biosimilar

Latest News

  1. Native American tribe moves to dismiss Allergan patent case
  2. Generic Drug Makers Face Pricing Issues That Other Pharmas Don't
  3. Mylan Down 24% Year to Date: What's Troubling the Stock?
  4. Mylan Plans to File Application for Revefenacin in Late 2017
  5. Mylan and Multiple Partnerships to Advance Biosimilar Portfolio
  6. Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver?
  7. Tax inversion deals saved U.S. companies $45 mln on average -CBO
  8. Could Mylan See a Rise in Net Profit Margins in 2017?
  9. Why Mylan Lowered Its Revenue Guidance for 2017
  10. Analysts’ Recommendations for Mylan in September 2017
  11. Teva: When Bold Action Just Isn't Possible
  12. Why Allergan Could Be A $300 Stock
  13. Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle
  14. Own Alphabet Inc. Stock? Antitrust Is on the Horizon
  15. ETFs with exposure to Mylan NV : September 14, 2017
  16. Challenge of Allergan tribal patent deal in uncharted legal territory
  17. Biosimilar 2017 Progress Report: Stocks in Focus
  18. Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets
  19. Mylan NV :MYL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  20. Mylan Names Dennis Zeleny as Chief Human Relations Officer